LOS ALTOS, Calif., Sept. 7, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. UNCY, a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.
A link to the webcast will be available on September 13, 2021 and may be accessed on the Unicycive website under the Investors section:Events and Presentations. An archive of the webcast will be available for three months.
About Unicycive
Unicycive is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com.
Contacts:
Remy Bernarda
ir@unicycive.com
(650) 900-5470
View original content to download multimedia:https://www.prnewswire.com/news-releases/unicycive-therapeutics-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301369986.html
SOURCE Unicycive Therapeutics Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.